Health Care • Biotechnology: Pharmaceutical Preparations
$28.71 ▼ -0.19
(-0.66%)
MKT CAP: $2.02B • VOL: 806.3K
52W L $16 52W H $31
ZYME // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $106.0M | $76.3M | $76.0M |
| YoY Revenue Growth % | +38.9% | +0.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$92.5M | -$137.1M | -$138.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$81.1M | -$122.7M | -$118.7M |
| EBITDA (Normalized) | -$91.3M | -$135.5M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$33.0M | -$110.1M | -$118.3M |
| Capital Expenditures (CapEx) | $1.5M | $2.0M | — |
| Free Cash Flow (FCF) | -$34.5M | -$112.0M | -$118.3M |
| FCF Margin % | -32.6% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -32.2% | -39.7% | — |
| Cash & Short-Term Equivalents | $41.2M | $66.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $268.5M | $338.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZYME.